Published in:
01-04-2022 | Research Article
Individualized Graves’ disease remission rates conversations: a videographic analysis of medical encounters
Authors:
Jessica Hidalgo, Sebastián Vallejo, Omar M. El Kawkgi, Naykky M. Singh Ospina, Spyridoula Maraka, Juan P. Brito
Published in:
Endocrine
|
Issue 1/2022
Login to get access
Excerpt
Graves’ disease (GD) is the most common cause of hyperthyroidism, with a lifetime probability of 2.9% for women and 0.5% for men [
1]. Because of the many metabolic effects of abnormally elevated thyroid hormone levels, GD is associated with many debilitating symptoms; and over time, GD decreases the quality of life with an impact on physical and social function, mental health, and overall wellbeing. There are three treatments for GD: thyroidectomy, radioactive iodine, and antithyroid drugs (ATDs). These options differ in their efficacy (i.e., remission), safety, convenience, and costs; none is clearly superior to the others for all patients [
2]. Yet, remission rate has been identified as the most important attribute that influences treatment decision-making [
3]. …
